Literature DB >> 28121507

Systemic Therapy for Metastatic Renal-Cell Carcinoma.

Toni K Choueiri1, Robert J Motzer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28121507     DOI： 10.1056/NEJMra1601333

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  326 in total

1.  Outcomes of Multi-disciplinary Management of Metastatic Renal Cell Carcinoma.

Authors:  Michael Yan; Richard Gregg; Aamer Mahmud
Journal:  Cureus       Date:  2019-10-13

2.  Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study.

Authors:  Anas M Saad; Mohamed M Gad; Muneer J Al-Husseini; Inas A Ruhban; Mohamad Bassam Sonbol; Thai H Ho
Journal:  Clin Genitourin Cancer       Date:  2018-10-11       Impact factor: 2.872

3.  Renal cell carcinoma with isolated breast metastasis.

Authors:  Sarah M Dhannoon; Ali A Alsaad; Abdo R Asmar; Fuad H Shahin
Journal:  BMJ Case Rep       Date:  2017-06-15

4.  Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.

Authors:  A Ari Hakimi; Martin H Voss; Fengshen Kuo; Alejandro Sanchez; Ming Liu; Briana G Nixon; Lynda Vuong; Irina Ostrovnaya; Ying-Bei Chen; Victor Reuter; Nadeem Riaz; Yuan Cheng; Parul Patel; Mahtab Marker; Albert Reising; Ming O Li; Timothy A Chan; Robert J Motzer
Journal:  Cancer Discov       Date:  2019-01-08       Impact factor: 39.397

Review 5.  Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma.

Authors:  Kyrollis Attalla; Stanley Weng; Martin H Voss; A Ari Hakimi
Journal:  Urol Clin North Am       Date:  2020-06-10       Impact factor: 2.241

6.  Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.

Authors:  Shreyas S Joshi; Elizabeth A Handorf; Matthew Zibelman; Elizabeth R Plimack; Robert G Uzzo; Alexander Kutikov; Marc C Smaldone; Daniel M Geynisman
Journal:  Eur Urol       Date:  2018-06-05       Impact factor: 20.096

7.  Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.

Authors:  Xin Gao; Opeyemi Jegede; Connor Gray; Paul J Catalano; Jesse Novak; David J Kwiatkowski; Rana R McKay; Daniel J George; Toni K Choueiri; David F McDermott; Sabina Signoretti; Rupal S Bhatt
Journal:  Clin Genitourin Cancer       Date:  2018-04-25       Impact factor: 2.872

Review 8.  Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?

Authors:  Nieves Martinez Chanza; Abhishek Tripathi; Lauren C Harshman
Journal:  Curr Treat Options Oncol       Date:  2019-05-03

9.  PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.

Authors:  Toni K Choueiri; Sabina Signoretti; Abdallah Flaifel; Wanling Xie; David A Braun; Miriam Ficial; Ziad Bakouny; Amin H Nassar; Rebecca B Jennings; Bernard Escudier; Daniel J George; Robert J Motzer; Michael J Morris; Thomas Powles; Evelyn Wang; Ying Huang; Gordon J Freeman
Journal:  Clin Cancer Res       Date:  2019-08-01       Impact factor: 12.531

10.  Dynamic changes of different phenotypic and genetic circulating tumor cells as a biomarker for evaluating the prognosis of RCC.

Authors:  Zhen-Long Wang; Peng Zhang; He-Cheng Li; Xiao-Jie Yang; Ya-Ping Zhang; Zhao-Lun Li; Li Xue; Yu-Quan Xue; Hong-Liang Li; Qi Chen; Tie Chong
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.